The global colorectal cancer diagnostics and therapeutics market was valued at USD XX billion in 2020 and is expected to grow with a CAGR of 4.7 % over the forecast period. The driving factors influencing the global colorectal cancer diagnostics and therapeutics market include the increasing prevalence of cancer therapies, growing number of colorectal cancer screening tests such as sigmoidoscopy, biopsy, CT colonography, and double-contrast barium enema. Moreover, due to the rising population, growing awareness towards colorectal cancer, increasing government initiatives for people suffering from colorectal cancer therapeutics the demand for global colorectal cancer diagnostics and therapeutics market is expected to witness lucrative growth over the forecast period.
With the increasing cost of cancer drugs the global colorectal cancer diagnostics and therapeutics market is facing crucial challenges in the growth of the market. Moreover, due to the loss of patients with cancer drugs, the demand for global colorectal cancer diagnostics and therapeutics market is expected to hamper the growth.
In the recent past, the global colorectal cancer diagnostics and therapeutics market has witnessed a drastic change owing to the introduction of Bevacizumab which is a monoclonal antibody that allows tumors from increasing blood vessels. This helps cure tumors and generate new blood vessel formation. The FDA has approved an extension for bevacizumab. This is an amalgamation with intravenous 5-fluorouracil-based chemotherapy and metastatic carcinoma of the rectum and colon. Thus, this boosts the global colorectal cancer diagnostics and therapeutics market.
Colorectal cancer is considered as the second most cause of cancer with the highest death rate in the United States. Colorectal cancer is expected to register over 9% of cases from all cancer incidences and is believed to be a significant cause of mortality across the globe. However, this increases demands for the global colorectal cancer diagnostics and therapeutics market with tremendous growth.
The global colorectal cancer diagnostics and therapeutics market is categorized into several segmentations including diagnostics techniques overview, modality overview, service overview, security type, deployment type, organization size, vertical industry, and regions. Based on the diagnostics techniques overview, the global colorectal cancer diagnostics and therapeutics market is fragmented into Stool Tests, Immunohistochemistry, Colonoscopy, Flexible Sigmoidoscopy, and Other Diagnostics Techniques. Based on the modality overview, the global colorectal cancer diagnostics and therapeutics market is segregated into Therapeutics, Chemotherapy, Antimetabolites, Fluorouracil, Capecitabine, Alkylating Agent Oxaliplatin, Immunotherapy, Bevacizumab, Cetuximab, Panitumumab, Chemoprotectant, and Other Chemotherapeutic Agents. The modality segment is about to project faster growth along with tremendous popularity in the market owing to the increasing population of towards colorectal cancer and increasing government initiatives for people suffering from colorectal cancer therapeutics the demand for global colorectal cancer diagnostics and therapeutics market is expected to witness lucrative growth over the forecast period.
North America is anticipated to hold the largest market size in the colorectal cancer diagnostics and therapeutics market, followed by Europe. This is due to the increasing presence of key vendors in the region. Furthermore, Europe is expected to hold the highest market size in the market resulting in GDPR compliance. Due to the increasing technological advancement in Asia Pacific region, the factors influencing the colorectal cancer diagnostics and therapeutics market include increasing prevalence of cancer therapies, growing number of colorectal cancer screening tests such as sigmoidoscopy, biopsy, CT colonography, and double-contrast barium enema are expected to project lucrative growth over the forecast period.
In terms of market players, the global colorectal cancer diagnostics and therapeutics market is competitive and fragmented with the presence of various kind of different vendors including Abbott Laboratories, Beckman Coulter, Clinical Genomics, Companion DX, EDP Biotech, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, Quest Diagnostics, Siemens Healthineers, and VolitionRX, among others.
With the increasing cost of cancer drugs the global colorectal cancer diagnostics and therapeutics market is facing crucial challenges in the growth of the market. Moreover, due to the loss of patients with cancer drugs, the demand for global colorectal cancer diagnostics and therapeutics market is expected to hamper the growth.
In the recent past, the global colorectal cancer diagnostics and therapeutics market has witnessed a drastic change owing to the introduction of Bevacizumab which is a monoclonal antibody that allows tumors from increasing blood vessels. This helps cure tumors and generate new blood vessel formation. The FDA has approved an extension for bevacizumab. This is an amalgamation with intravenous 5-fluorouracil-based chemotherapy and metastatic carcinoma of the rectum and colon. Thus, this boosts the global colorectal cancer diagnostics and therapeutics market.
Colorectal cancer is considered as the second most cause of cancer with the highest death rate in the United States. Colorectal cancer is expected to register over 9% of cases from all cancer incidences and is believed to be a significant cause of mortality across the globe. However, this increases demands for the global colorectal cancer diagnostics and therapeutics market with tremendous growth.
The global colorectal cancer diagnostics and therapeutics market is categorized into several segmentations including diagnostics techniques overview, modality overview, service overview, security type, deployment type, organization size, vertical industry, and regions. Based on the diagnostics techniques overview, the global colorectal cancer diagnostics and therapeutics market is fragmented into Stool Tests, Immunohistochemistry, Colonoscopy, Flexible Sigmoidoscopy, and Other Diagnostics Techniques. Based on the modality overview, the global colorectal cancer diagnostics and therapeutics market is segregated into Therapeutics, Chemotherapy, Antimetabolites, Fluorouracil, Capecitabine, Alkylating Agent Oxaliplatin, Immunotherapy, Bevacizumab, Cetuximab, Panitumumab, Chemoprotectant, and Other Chemotherapeutic Agents. The modality segment is about to project faster growth along with tremendous popularity in the market owing to the increasing population of towards colorectal cancer and increasing government initiatives for people suffering from colorectal cancer therapeutics the demand for global colorectal cancer diagnostics and therapeutics market is expected to witness lucrative growth over the forecast period.
North America is anticipated to hold the largest market size in the colorectal cancer diagnostics and therapeutics market, followed by Europe. This is due to the increasing presence of key vendors in the region. Furthermore, Europe is expected to hold the highest market size in the market resulting in GDPR compliance. Due to the increasing technological advancement in Asia Pacific region, the factors influencing the colorectal cancer diagnostics and therapeutics market include increasing prevalence of cancer therapies, growing number of colorectal cancer screening tests such as sigmoidoscopy, biopsy, CT colonography, and double-contrast barium enema are expected to project lucrative growth over the forecast period.
In terms of market players, the global colorectal cancer diagnostics and therapeutics market is competitive and fragmented with the presence of various kind of different vendors including Abbott Laboratories, Beckman Coulter, Clinical Genomics, Companion DX, EDP Biotech, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, Quest Diagnostics, Siemens Healthineers, and VolitionRX, among others.
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
